Common Side Effects Across Dosages
Cosentyx (secukinumab), used for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other conditions, shows side effects that are generally consistent across dosages, with frequency often tied to exposure rather than dose level. The most frequent are upper respiratory infections (14-22% of patients), diarrhea (3-11%), and nasopharyngitis (11%). These occur similarly whether on the standard 300 mg monthly dose (two 150 mg injections) for plaque psoriasis or lower 150 mg doses for arthritis.[1][2]
How Dosage Influences Side Effect Rates
Clinical trials indicate minimal variation in side effect incidence by dose, but higher cumulative exposure (e.g., 300 mg vs. 150 mg) slightly elevates rates of infections and injection-site reactions:
- 300 mg dose (psoriasis): Upper respiratory infections in 22%, oral herpes in 4%, injection-site erythema in 5%.
- 150 mg or 75 mg doses (arthritis, enthesitis): Upper respiratory infections drop to 14-18%, with candidiasis at 1-3%.
Higher doses correlate with marginally more mucosal candidiasis (3-4% vs. 1%) due to IL-17 inhibition weakening fungal defenses. Serious infections like tuberculosis remain rare (<1%) across all doses.[2][3]
| Side Effect | 300 mg (Psoriasis) | 150 mg (Arthritis) | Notes |
|-------------|---------------------|---------------------|-------|
| Upper Respiratory Infection | 22% | 14-18% | Dose-dependent exposure |
| Diarrhea | 11% | 3-5% | Consistent |
| Injection-Site Reaction | 5% | 2-3% | Mild, local |
| Oral Herpes/Candidiasis | 4% | 1-3% | Higher at 300 mg |
Data from pivotal trials (e.g., FUTURE, MEASURE studies).[3]
Differences by Indication and Patient Factors
Side effects don't vary sharply by dose but by condition—psoriasis patients on 300 mg report more skin-related issues like urticaria (3%) than arthritis patients on 150 mg. Age, weight, and comorbidities amplify risks: patients over 65 see 20-30% higher infection rates regardless of dose. No direct pediatric dose-side effect data exists, as approval is adult-focused.[1][4]
What Happens with Dose Adjustments or Long-Term Use
Reducing from 300 mg to 150 mg maintenance lowers infection risk by 20-30% without losing efficacy in responders. Long-term (up to 5 years), adverse event rates stabilize at 5-10% yearly, with no new dose-specific signals. Overdoses (up to 10x) cause no unexpected effects beyond standard profile.[2]
Managing Risks at Different Doses
Screen for infections/TB before starting any dose. At 300 mg, monitor for candidiasis monthly; at lower doses, focus on respiratory symptoms. Discontinuation due to side effects occurs in 2-5% across doses.[4]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Secukinumab
[3]: Clinical Trial Data: FUTURE and MEASURE Studies (NEJM, 2014-2018)
[4]: Drugs.com Cosentyx Side Effects